New ATC 5th levels 2023
| ATC code | ATC level name |
|---|---|
| A01AB24 | octenidine |
| A01AB25 | oxytetracyline |
| A01AC04 | prednisolone |
| A02BX15 | teprenone |
| A03FA10 | acotiamide |
| A05BA10 | phospholipids |
| A06AX09 | elobixibat |
| A08AA51 | phentermine and topiramate |
| A10BX16 | tirzepatide |
| A10BX17 | carfloglitazar |
| A10BX18 | dorzagliatin |
| A16AB23 | cipaglucosidase alfa |
| A16AB24 | pegzilarginase |
| A16AB25 | olipudase alfa |
| A16AX21 | elivaldogene autotemcel |
| A16AX22 | tiomolibdic acid |
| B06AX04 | mitapivat |
| C01EB24 | mavacamten |
| C02KX54 | macitentan and tadalafil |
| C09BB13 | benazepril and amlodipine |
| C09DX08 | telmisartan, amlodipine and hydrochlorothiazide |
| C10BX19 | atorvastatin, amlodipine and candesartan |
| D01AC21 | neticonazole |
| D01AC22 | lanoconazole |
| D01AE25 | liranaftate |
| D11AH09 | ruxolitinib |
| G01AF21 | tinidazole |
| G02CX06 | fezolinetant |
| G04BD14 | imidafenacin |
| G04CA55 | doxazosin and finasteride |
| G04CB51 | finasteride and tadalafil |
| H01AC09 | lonapegsomatropin |
| H01CC53 | elagolix, estradiol and norethisterone |
| H02CA04 | levoketoconazole |
| H03AA51 | levothyroxine sodium and iodine compounds |
| H04AA02 | dasiglucagon |
| J01RA16 | cefixime and azithromycin |
| J02AX07 | ibrexafungerp |
| J02AX08 | rezafungin acetate |
| J04BA50 | dapsone and rifampicin |
| J04BA51 | dapsone, rifampicin and clofazimine |
| J05AB18 | molnupiravir |
| J05AE30 | nirmatrelvir and ritonavir |
| J06BD04 | ansuvimab |
| J06BD05 | sotrovimab |
| J06BD06 | regdanvimab |
| J06BD07 | casirivimab and imdevimab |
| J06BD08 | nirsevimab |
| J07AX01 | leptospira vaccines |
| J07BN01 1) | covid-19, RNA-based vaccine |
| J07BN02 1) | covid-19, viral vector, non-replicating |
| J07BN03 1) | covid-19, inactivated virus |
| J07BN04 1) | covid-19, protein subunit |
| J07XA01 | malaria vaccines |
| L01CD51 | paclitaxel and encequidar |
| L01EB09 | lazertinib |
| L01EB10 | mobocertinib |
| L01EB11 | aumolertinib |
| L01EG04 | sirolimus |
| L01EM05 | parsaclisib |
| L01EX24 | surufatinib |
| L01EX25 | umbralisib |
| L01FD06 | margetuximab |
| L01FX19 | sabatolimab |
| L01FX20 | tremelimumab |
| L01FX21 | naxitamab |
| L01FX22 | loncastuximab tesirine |
| L01FX23 | tisotumab vedotin |
| L01XL05 | ciltacabtagene autoleucel |
| L01XL06 | brexucabtagene autoleucel |
| L01XL07 | idecabtagene vicleucel |
| L01XX75 | tebentafusp |
| L01XX77 | adagrasib |
| L01XY03 | nivolumab and relatlimab |
| L03AA18 | efbemalenograstim alfa |
| L04AA57 | ublituximab |
| L04AA58 | efgartigimod alfa |
| L04AA59 | avacopan |
| L04AC23 | olokizumab |
| M03BX53 | pridinol, combinations |
| M05BX08 | menatetrenone |
| N04BA07 | foslevodopa and decarboxylase inhibitor |
| N05AH53 | olanzapine and samidorphan |
| N06AX29 | brexanolone |
| N06BA15 | dexmethylphenidate and serdexmethylphenidate |
| N07XX18 | vutrisiran |
| R02AD05 | ambroxol |
| R06AA61 | dimenhydrinate, combinations |
| S01AA29 | dibekacin |
| S01AA31 | cefmenoxime |
| S01AE09 | tosufloxacin |
| S01KX02 | trypan blue |
| S01LA09 | faricimab |
| S01XA28 | varenicline |
| S01XA29 | sepofarsen |
| S02AA17 | fosfomycin |
| S02AA18 | cefmenoxime |
| S03CA07 | methylprednisolone and antiinfectives |
| V04CX10 | pafolacianine |
| V08CA12 | gadopiclenol |
| V09AX07 | flortaucipir (18F) |
| V09IX15 | copper (64Cu) dotatate |
| V09IX16 | piflufolastat (18F) |
| V09IX17 | PSMA-1007 (18F) |
| V10XX05 | lutetium (177Lu) vipivotide tetraxetan |
1) J07BX03 covid-19 vaccines deleted. Covid-19 vaccines subdivided into new 5th levels in a new 4th level J07BN.
Last updated: 2022-11-25